Cardiology

Liraglutide Labeling Updated With Cardiovascular Safety Data




The randomized, double-blind, placebo-controlled, parallel-group study (N=9340) evaluated the time from randomization to first occurrence of major adverse CV events (MACE) (non-fatal heart attack, non-fatal stroke, CV death) in patients treated with liraglutide 1.8mg once daily or placebo.

Source link





Related posts

Could Your Racing Heart be Caused by Caffeine?

Newsemia

Depression and Heart Disease

Newsemia

Thomas Bevill Peacock and the First Descriptions of Congenital Heart Disease.

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy